Bioworld -- It’s not exactly the best of times for biotechnology, although its recession-proof innovation is still in high demand. Conversely, it is not patently the worst of times for pharma, even as it swims upstream against an underway rising tide of encroaching generics, lean pipelines and innovator’s block. However, it can be propitious times for both and a ground-breaking start to the future of the next new era in drug development, as collaborative, and assimilative, metrics delineate the industries that will produce therapeutics for the twenty-first century market.
